|Security||AMPE / Ampio Pharmaceuticals, Inc.|
|Institution||Mml Investors Services, Llc|
Mml Investors Services, Llc closes position in AMPE / Ampio Pharmaceuticals, Inc.
August 13, 2018 - Mml Investors Services, Llc has filed a 13F-HR form disclosing ownership of 0 shares of Ampio Pharmaceuticals, Inc. (AMEX:AMPE) with total holdings valued at $0 USD as of June 30, 2018. Mml Investors Services, Llc had filed a previous 13F-HR on May 11, 2018 disclosing 14,500 shares of Ampio Pharmaceuticals, Inc. at a value of $49,000 USD. This represents a change in shares of -100.00 percent and a change in value of -100.00 percent during the quarter.
Ampio Pharmaceuticals, Inc. has declared a standard industrial code (sic) of 2834 which is the "Pharmaceutical Preparations" industry. Mml Investors Services, Llc's top industries are "Real Estate" (sic 65), "Transportation Services" (sic 47), and "Amusement And Recreation Services" (sic 79).
The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.
In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.
Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.
2018-09-03 - Asif
Executive summary Ampio Pharmaceuticals is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. The company's therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. The pharmaceutical market is a competitive industry with strict regulations that are time intensive and costly. However, Ampio Pharmaceuticals is committed to offer compelling therapeutic options for the patients most in need of new treatment o...
as of ET